A "first of its kind" personalized DNA vaccine is doubling survival rates for patients with aggressive glioblastoma. By targeting 40 unique tumor proteins, twice as many as previous therapies, the GNOS-PV01 vaccine transforms "cold" tumors into "hot" targets for the immune system. With one patient remaining cancer-free five years late.
